Abstract:BACKGROUND:Oxaliplatin is one of the most commonly used chemotherapeutic agent for the treatment of various cancers, including gastric cancer. It has, however, a narrow therapeutic index due to its toxicity and the occurrence of drug resistance. Hence, it is of great significance to develop novel therapies to potentiate the anti-tumor effect and reduce the toxicity of oxaliplatin. In our previous study, we demonstrated that ethaselen (BBSKE), an inhibitor of thioredoxin reductase, effectively inhibited the growth of gastric cancer cells and promoted apoptosis in vitro. In the present study, we investigated whether BBSKE can potentiate the anti-tumor effect of oxaliplatin in gastric cancer in vivo and vitro.METHODS:Cellular apoptosis and ROS levels were analyzed by flow cytometry. Thioredoxin reductase 1 (TrxR1) activity in gastric cancer cells, organoid and tumor tissues was determined by using the endpoint insulin reduction assay. Western blot was used to analyze the expressions of the indicated proteins. Nude mice xenograft models were used to test the effects of BBSKE and oxaliplatin combinations on gastric cancer cell growth in vivo. In addition, we also used the combined treatment of BBSKE and oxaliplatin in three cases of gastric cancer Patient-Derived organoid (GC-PDO) to detect the anti-tumor effect.RESULTS:We found that BBSKE significantly enhanced oxaliplatin-induced growth inhibition in gastric cancer cells by inhibiting TrxR1 activity. Because of the inhibition of TrxR1 activity, BBSKE synergized with oxaliplatin to enhance the production of ROS and activate p38 and JNK signaling pathways which eventually induced apoptosis of gastric cancer cells. In vivo, we also found that BBSKE synergized with oxaliplatin to suppress the gastric cancer tumor growth in xenograft nude mice model, accompanied by the reduced TrxR1 activity. Remarkably, we found that BBSKE attenuated body weight loss evoked by oxaliplatin treatment. We also used three cases of GC-PDO and found that the combined treatment of BBSKE and oxaliplatin dramatically inhibited the growth and viability of GC-PDO with increased ROS level, decreased TrxR1 activity and enhanced apoptosis.CONCLUSIONS:This study elucidates the underlying mechanisms of synergistic effect of BBSKE and oxaliplatin, and suggests that the combined treatment has potential value in gastric cancer therapy.

Novel Thioredoxin Reductase Inhibitor Butaselen Inhibits Tumorigenesis by Down-Regulating Programmed Death-Ligand 1 Expression

Butaselen Prevents Hepatocarcinogenesis and Progression Through Inhibiting Thioredoxin Reductase Activity

A Novel TrxR1 Inhibitor Regulates NK and CD8+T Cell Infiltration and Cytotoxicity, Enhancing the Efficacy of Anti-PD-1 Immunotherapy Against Hepatocarcinoma

Therapeutic Effects of an Inhibitor of Thioredoxin Reductase on Liver Fibrosis by Inhibiting the Transforming Growth Factor-β1/Smads Pathway

TrxR/Trx inhibitor butaselen ameliorates pulmonary fibrosis by suppressing NF-κB/TGF-β1/Smads signaling

TrxR/Trx inhibitor butaselen ameliorates pulmonary fibrosis by suppressing NF-B/TGF-1/Smads signaling

A Novel Thioredoxin Reductase Inhibitor Inhibits Cell Growth and Induces Apoptosis in HL-60 and K562 Cells

Thioredoxin Reductase Inhibitor Ethaselen Inhibits Cancer Metastasis

Bexarotene: a Promising Anticancer Agent

The Antimetastatic Effect and Underlying Mechanisms of Thioredoxin Reductase Inhibitor Ethaselen.

The mechanism of apoptosis induced by a novel thioredoxin reductase inhibitor in A549 cells: Possible involvement of nuclear factor-κB-dependent pathway

Arsenic trioxide promotes ERK1/2-mediated phosphorylation and degradation of BIMEL to attenuate apoptosis in BEAS-2B cells

A thioredoxin reductase inhibitor induces growth inhibition and apoptosis in five cultured human carcinoma cell lines.

A Novel Organoselenium Compound Induces Cell Cycle Arrest and Apoptosis in Prostate Cancer Cell Lines.

Promotion of SIRT1 Protein Degradation and Lower SIRT1 Gene Expression Via Reactive Oxygen Species is Involved in Sb-induced Apoptosis in BEAS-2b Cells

Mkp-1 is required for chemopreventive activity of butylated hydroxyanisole and resveratrol against colitis-associated colon tumorigenesis.

Pharmacological Inhibition of TXNRD1 by a Small Molecule Flavonoid Butein Overcomes Cisplatin Resistance in Lung Cancer Cells

Biological Evaluation of Novel Selenazole-Based Compounds As Potential Thioredoxin Reductase Inhibitors

Suppression of signal transducer and activator of transcription 3 activation by butein inhibits growth of human hepatocellular carcinoma in vivo.

Selenium-containing Thioredoxin Reductase Inhibitor Ethaselen Sensitizes Non-Small Cell Lung Cancer to Radiotherapy

Ethaselen Synergizes with Oxaliplatin in Tumor Growth Inhibition by Inducing ROS Production and Inhibiting TrxR1 Activity in Gastric Cancer